welcome to iuvantium

a precision immunology company

our name is based on the Latin word “iuvare” [i̯u:vare] – to help, aid

in vaccines a key functional ingredient is the “adjuvant”

from “adiuvo” [ˈäd̪juvo] –“I help, assist”

iuvantium mundum – “helping the world”

our VISION

A world in which we can treat, cure, and protect everyone everywhere from disease so that we, together, become stronger.

our MISSION

At iuvantium, we’re spearheading the fight against the silent pandemic that is antimicrobial resistance (AMR) and cancer. By blending cutting-edge material science, translational immunology, and ML/AI, we’re engineering precision immunology to enable the next generation of vaccines and therapeutics.

our VALUES

We believe in people and that all deserve the best possible treatment to live, thrive and do good.

Great isn’t just good enough. We do our best work when we excel as a team.

Nana korobi, ya oki – “Fall down seven times, stand up 8.”

We build trust through responsible actions and honest relationships.

We are convinced that collaboration is the key to true innovation.

Innovation = Invention x Commercialization

We embrace the infinite game – we always take the long view.

the PROBLEM

The Tide is Turning - Antibiotics Were Effective - Till Now

Antimicrobial resistance (AMR) could wipe out 2 years of global life expectancy

2 years by 2035 amounts to

25% of the only 8 years we gained in the last FOUR decades.

This is a mindboggeling development for which there is no real solution.

our APPROACH

We Believe in Prevention Over Treatment

We are convinced that the only proven and viable long-term solution to replacing failing antibiotics is developing vaccines against drug-resistant bacteria.

Bacteria develop

resistance against antibiotics, NOT against effective vaccines.

They offer life-long protection.

our SOLUTION

to fight bacteria we need to activate the right parts of the immune system

Current adjuvants and immune modulators fail to induce the right type of immmune response.

Any vaccine formulations trialled so far,

failed to induce a potent Th17 response safely.

iuvantium has the technology to make the impossible possible.

our Technology

we developed a rationally designed and engineered inorganic precision immune modality

99% of vaccinology focuses on the antigen,

dismissing the fact that vaccines need adjuvants to be effective.

iuvantium is the only company to precisely engineer immunogenicity with our inorganic adjuvant platform.

The modality is disease and antigen agnostic.

It can be tailored to a specific pathogen, for a specific antigen, targeting a specific patient population.

our Process

our proprietary design and manufacturing process provides us with unprecendented control